Athira Pharma, Inc. — Director's Dealing 2021

Feb 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2021-02-03

Reporting Person: FLUKE JOHN M JR (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-03	Common Stock	M	25220	$1.19	Acquired	140101	Direct
2021-02-03	Common Stock	M	3783	$1.35	Acquired	143884	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-03	Stock Option (Right to Buy)	$1.19	M	25220	Disposed	2027-12-12	Common Stock (25220)	Direct
2021-02-03	Stock Option (Right to Buy)	$1.35	M	3783	Disposed	2030-01-28	Common Stock (3783)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	6731	Indirect

Footnotes

F1: This filing relates to the exercise of stock options. No shares of Common Stock were sold by Mr. Fluke, and the shares of Common Stock received upon exercise of the stock options are subject to lock-up agreements with Goldman Sachs & Co. LLC and Jefferies LLC.

F2: The shares subject to the option fully vested on December 13, 2020.

F3: The shares subject to the option fully vested on December 13, 2019.